



**BioMarker**  
STRATEGIES

## ***News Release***

---

**Contact:**

**Scott Allocco, President**

**410-522-1008**

**[sallocco@biomarkerstrategies.com](mailto:sallocco@biomarkerstrategies.com)**

**Embargoed for Release**

May 27, 2011

### **BioMarker Strategies Appoints Glenn Miller to Board of Directors as Chairman**

Baltimore, MD---BioMarker Strategies announced today that it has appointed Glenn A. Miller, PhD, to its Board of Directors, where he will serve as Chairman. Dr. Miller had previously served on the company's Scientific Advisory Board. The company also announced that its cofounder, Dr. Douglas P. Clark, will become the Chief Medical Officer and Acting CEO of the company starting July 1, 2011.

"Dr. Miller has spent his entire career advancing personalized medicine and molecular pathology, so we are thrilled that he has agreed to join our effort to transform these fields with our SnapPath™ live tumor cell testing system," said Christy Wyskiel, the company's current Chairman, who will remain a Director of the company. "We are also very pleased that Dr. Clark will be joining us full time to propel the company forward and direct our clinical studies."

Other Directors at the company include: Dr. Samuel Broder, a former Director of the National Cancer Institute; Dr. Mark Velleca, a strategic advisor to Gilead Sciences; Dr. Paul Beresford, a VP of Business Development at Biodesix and a former VP of Translational Diagnostics at Ventana Medical Systems; Skip Klein, Managing Member at Gauss Capital Advisory and founder of the T. Rowe Price Health Sciences Fund; and company cofounder and President Scott Allocco, a former VP of State Government Affairs at Coventry Healthcare.

#### **About Glenn Miller, PhD**

Glenn A. Miller, PhD, was recently named Vice President and Head of Strategy, Portfolio and Alliances for Personalized Healthcare & Biomarkers at AstraZeneca Pharmaceuticals, LP.

Prior to accepting this position in April of 2011, he served for nearly 20 years at Genzyme Genetics, where he was most recently the Vice President and General Manager of a division of Genzyme Genetics, Genzyme Analytical Services. Genzyme Genetics was one of the five largest clinical laboratories in the United States when Labcorp acquired it for \$925M in 2010. The company's Analytical Services division provided pathology-based technologies and molecular diagnostic testing services to the biopharmaceutical industry world-wide.

Dr. Miller has published and spoken extensively in the areas of genetics, pharmacogenomics and personalized medicine. Dr. Miller is a member of the Clinical Sciences Committee of the Personalized Medicine Coalition, has served as a member of the European Federation of Pharmaceutical Industries and Associations Pharmacogenetics ad hoc group and as a member of

NEWS Release

the Human Genome Organization strategy session on Future Directions of Human Genome Research in Europe.

Dr. Miller received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo. He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami School of Medicine.

### **About Douglas P. Clark, MD**

Dr. Douglas P. Clark is currently a Professor of Pathology and Oncology at The Johns Hopkins Medical Institutions, where he served as the director of the Division of Cytopathology from 2002-2010. Effective July 1, he will be taking a leave of absence to join BioMarker Strategies full time. He is a board-certified anatomic pathologist and cytopathologist with experience in oncology, micro-biology and molecular diagnostics. He serves on the editorial boards of *Cancer Cytopathology* and *Expert Review of Molecular Diagnostics*.

Dr. Clark has been at the forefront of efforts to integrate molecular biomarkers into the field of pathology. At Johns Hopkins, he successfully developed a comprehensive molecular cytopathology program that serves as a vital resource to clinical trial development, particularly in the area of oncology. This work has led to numerous publications and a patent for a targeted therapy-related diagnostic test that has been licensed by BioMarker Strategies. He also served as the Chairman of the Scientific Committee of the American Cytopathology Society (ASC) from 2006-2008. Dr. Clark has also served on the Biospecimen Reporting for Improved Study Quality (BRISQ) Committee, sponsored by the National Cancer Institute, which is developing national guidelines for research involving biospecimens.

Dr. Clark received his M.D. degree from The Johns Hopkins School of Medicine and his B.A. degree in biochemistry and molecular biology from Northwestern University.

### **About BioMarker Strategies**

BioMarker Strategies is developing the SnapPath™ live tumor cell testing system to enable next-generation biomarker tests for solid-tumor based cancers. The SnapPath™ system incorporates an automated, live-tumor-cell processing device with first-in-class, functional, ex vivo biomarker tests to inform clinical decision making for targeted cancer therapeutics. SnapPath™ stimulates a patient's live tumor cells outside their body to obtain a Functional Signaling Profile (FSP™) of the signal transduction network that is not possible using static, genomic biomarkers from dead, fixed tissue. The company is located at the Johns Hopkins Science + Technology Park in East Baltimore. The development of the SnapPath™ system is supported with significant funding from the National Cancer Institute. For more information about BioMarker Strategies, please refer to [www.biomarkerstrategies.com](http://www.biomarkerstrategies.com).

# # #

*Some of the information in this release contains our projections or other forward-looking statements regarding future events. We wish to caution you that these statements are only predictions and actual events or results may differ materially. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Forward-looking statements included herein are made as of the date hereof, and we undertake no obligation to update publicly such statements to reflect subsequent events or circumstances. Actual results could differ materially from anticipated results.*

# # #